Optimizing levodopa therapy, when and how? Perspectives on the importance of delivery and the potential for an early combination approach-Reference-Cited by-同舟云学术

Optimizing levodopa therapy, when and how? Perspectives on the importance of delivery and the potential for an early combination approach

Published:2023-01-02 Issue:1 Volume:23 Page:15-24
ISSN:1473-7175
Container-title:Expert Review of Neurotherapeutics
language:en
Short-container-title:Expert Review of Neurotherapeutics

Author:

Lees Andrew¹,Tolosa Eduardo²,Stocchi Fabrizio³,Ferreira Joaquim J.⁴⁵^ORCID,Rascol Olivier⁶,Antonini Angelo⁷,Poewe Werner⁸

Affiliation:

1. University College London, Reta Lila Weston Institute, London, UK

2. Parkinson disease and Movement Disorders Unit, Neurology Service, Hospital Clinic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) Barcelona, Barcelona, Spain

3. Department of Neurology, University San Raffaele and IRCCS San Raffaele Pisana, Rome, Italy

4. Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal

5. CNS – Campus Neurológico, Torres Vedras, Portugal

6. Department of Neurosciences and Clinical Pharmacology, Clinical Investigation center CIC1436 and NS-Park/FCRIN network; University Hospital of Toulouse, INSERM and University of Toulouse 3, Toulouse, France

7. Movement Disorders Unit, Study Center for Neurodegenerative Diseases (CESNE), Department of Neuroscience, University of Padova

8. Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria

Funder

No author received any remuneration for the preparation of this article

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Neurology (clinical),General Neuroscience

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737175.2023.2176220

Reference112 articles.

1. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030

2. The current and projected economic burden of Parkinson's disease in the United States

3. Parkinson disease

4. Neuropathological Staging of Brain Pathology in Sporadic Parkinson’s disease: Separating the Wheat from the Chaff

5. MDS research criteria for prodromal Parkinson's disease

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real‐world considerations regarding the use of the combination of levodopa, carbidopa, and entacapone (Stalevo^®) in Parkinson's disease;European Journal of Neurology;2023-10-15

2. How and why the adenosine A2A receptor became a target for Parkinson’s disease therapy;International Review of Neurobiology;2023